Dana-Farber Cancer Institute
Avatar

FLT3 Mutations in AML: What Is the Benefit of Midostaurin for Upfront Use? Is There a Clinical Significance of FLT3 Inhibitors in Relapsed Disease?

By Dana-Farber Cancer Institute FEATURING Richard Stone
By Dana-Farber Cancer Institute FEATURING Richard Stone
256 views
May 28, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Related Content

AUTOPLAY
22:37
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of Acute Leukemia and MDS - Highlig…

Feat. T. Badar
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
50:34
Scripps MD Anderson Cancer Center

The Cure of Leukemias in the Next Decade: An Optimist’s View

Feat. H. Kantarjian
19:10
5th SOHO Italy Annual Conference

SOHO Italy 2023: How I Treat AML at MD Anderson Cancer Center

Feat. H. Kantarjian
12:36
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Myeloid for Measure - New Therapeutics in…

Feat. A. Patel
09:51
i3 Health

MRD Testing in Leukemias: When Negativity Is a Positive Thing

Feat. N. S. Raje
12:33
SOHO 2022 Tenth Annual Meeting

SOHO 2022 Next Questions: AML

Feat. H. Kantarjian
14:19
Talha Badar

Challenges in the Management of TP53-Mutated AML: Potential Strategi…

44:26
University of Colorado Division of Hematology

Novel Therapies in AML and MDS

Feat. D. Pollyea
14:39
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Immunotherapies in Acute Leukemias: 2024 Update

Feat. C. Lai
22:30
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Emerging Treatment Options for AML in 2024

Feat. A. Perl
13:39
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Triplet Regimens in AML: Beyond Azacitidine + Venetoclax

Feat. C. DiNardo
27:28
UChicago Medicine

AML: Current Treatment Landscape and Key Recent Updates

Feat. A. Patel
12:28
Roswell Park Comprehensive Cancer Center

Current Landscape of R/R AML Treatment

Feat. E. Wang
02:52
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Results From a Phase 1 Clinical Study of …

Feat. M. Amaya
32:04
Moffitt Cancer Center

Experts Discuss the Latest Data in Myeloid Diseases

Feat. A. Kuykendall, R. Komrokji, O. Chan, D. Sallman
40:21
Fred Hutch 13th Annual Comprehensive Hematology & Oncology Review Course

Overview of Hematopoietic Cell Transplantation

Feat. R. Salit
15:45
SOHO 2022 Tenth Annual Meeting

SOHO 2022: How Do We Overcome Resistance to Venetoclax in AML

Feat. M. Konopleva
16:59
MyCancerHaven

Experts Discuss Current and Future Management of AML

Feat. R. Vij, N. Daver
18:48
Current Challenges in Hematology

Venetoclax-Based Combinations in Newly Diagnosed AML: A New Golden S…

Feat. C. DiNardo